CURRTechnology · Software - ApplicationCURR Stock Forecast: Currenc Group, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 1 Aug 2026 — in the lower half.
CURR stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Currenc Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Quality (14): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Currenc Group, Inc. — and when they’d sell — is the membership.
CURR stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CURR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Mar 2025 | Roth MKM | Initiates | Buy | $3.50 |
| 5 Mar 2025 | Roth MKM | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CURR analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Currenc Group, Inc. (CURR) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −11.0×
- Price / sales
- 9.9×
- Price / book
- —
- EV / EBITDA
- −62.3×
Cheaper than 93% of US stocks
Cheaper than 14% of US stocks
Cheaper than 95% of US stocks
- Revenue growth (YoY)
- −21.8%
- Earnings growth (YoY)
- −21.8%
- Gross margin
- 42.7%
- Operating margin
- −46.5%
- Net margin
- −48.7%
Higher than 11% of US stocks
Higher than 19% of US stocks
Higher than 55% of US stocks
Higher than 18% of US stocks
Higher than 10% of US stocks
- Return on equity
- −98.8%
- Return on assets
- −4.5%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 32% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
CURR vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CURR appears on the weeks it earns a place.
Frequently asked questions about CURR stock
Is CURR stock a buy right now?
Of the 1 analysts covering Currenc Group, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Currenc Group, Inc. 27 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CURR?
As at 1 Aug 2026, Currenc Group, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
What is the CURR stock forecast for 2030?
No analyst covering Currenc Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CURR are extrapolating price history, which says nothing about the business.
How has CURR stock performed over the past year?
Currenc Group, Inc. returned +62.3% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Currenc Group, Inc. do?
Cure Pharmaceutical Holding Corp. is a biopharmaceutical company focused on the development and commercialization of innovative drug delivery systems.
About Currenc Group, Inc.
Cure Pharmaceutical Holding Corp. is a biopharmaceutical company focused on the development and commercialization of innovative drug delivery systems. It aims to improve patient adherence and experience by providing new methods for drug delivery, such as oral thin films and transdermal systems. Cure Pharmaceutical's technologies are designed to enhance the bioavailability, efficacy, and safety of existing pharmaceutical compounds while also providing a platform for new drug formulations. This plays a vital role in several therapeutic areas, including pain management, oncology, and central nervous system disorders. By leveraging cutting-edge technology and partnerships within the pharmaceutical industry, Cure Pharmaceutical Holding Corp. contributes to the advancement of personalized and precision medicine, addressing unmet medical needs and broadening the spectrum of delivery options in healthcare markets.
CEO Mr. King Ong Kong · 293 employees · Singapore · https://investors.currencgroup.com